Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financi...(0 ...)

-------- --------

2008 2007 2008 2007

---- ---- ---- ----

Nexavar product revenue, net (as

recorded by Bayer) $168,520 $81,332 $320,416 $142,212

Revenue subject to profit sharing

(as recorded by Bayer) 156,547 81,332 308,443 142,212

Combined cost of goods sold,

distributed, selling, general and

administrative expenses 80,135 49,285 142,838 85,734

Combined research and development

expenses 43,946 34,856 81,424 68,146

------- ------- ------- -------

Combined collaboration profit

(loss) $32,466 $(2,809) $84,181 $(11,668)

------- -------- ------- ---------

Onyx's share of collaboration

profit (loss) $16,233 $(1,405) $42,091 $(5,834)

Reimbursement of Onyx's direct

development and marketing expenses 13,128 8,875 25,008 16,329

Royalty revenue 838 - 838 -

------ ------ ------ ------

Onyx net revenue from

unconsolidated joint business $30,199 $7,470 $67,937 $10,495

------- ------ ------- -------

ONYX PHARMACEUTICALS, INC.

CONDENSED BALANCE SHEETS

(In thousands)

Jun. 30, Dec. 31,

2008 2007

(unaudited)
'/>"/>